A fetal-origin decellularized nucleus pulposus (NP) allogenic material to regenerate a host's Intervertebral Disc (IVD). The decellularized NP material, obtained from a vertebrate fetus and characterized by comprising high levels of collagen 12 and 14, is used in a pharmacological composition for the treatment of IVD degeneration. The advance is based on the increased ability of the fetal decellularized NP material to stimulate the host constituent cell's to increase the expression of collagen 2 and aggrecan, promoting intrinsic IVD regeneration. A related method includes preparing the pharmaceutical compositions of fetal decellularized material in the form of fragments/microparticles and hydrogel for an injectable mode of administration. The involved material, pharmaceutical compositions and methods may be advantageously used for the prevention and treatment of IVD degeneration and back pain in human and veterinary settings.

Provided are an apparatus and method for injection of a fluid into a substrate. In some embodiments, an apparatus or method described herein delivers cells to a tissue scaffold, graft, or site of tissue injury to facilitate the repair of a tissue defect.

The present disclosure provides a method of bioprinting a 3-D structure comprising one or more biologically-relevant materials on a super-hydrophobic surface. In one embodiment, the method comprises providing a composition having one or more biologically-relevant materials dispersed within a biocompatible medium. A pattern comprising a hydrophilic material is deposited on a defined area of the super-hydrophobic surface, wherein the pattern is modeled after a biological structure. The composition having the one or more biologically-relevant materials is then bioprinted atop the hydrophilic surface to form a 3-D structure, wherein the hydrophilic surface maintains the 3-D structure in a desired position or shape on the super-hydrophobic surface.

It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10.

The present disclosure relates to a biocompatible patch and methods of use thereof. A biocompatible patch and uses thereof for treating a damaged cardiac tissue.

The inventions provided herein relate to compositions, methods, delivery devices and kits for repairing or augmenting a tissue in a subject. The compositions described herein can be injectable such that they can be placed in a tissue to be treated with a minimally-invasive procedure (e.g., by injection). In some embodiments, the composition described herein comprises a compressed silk fibroin matrix, which can expand upon injection into the tissue and retain its original expanded volume within the tissue for a period of time. The compositions can be used as a filler to replace a tissue void, e.g., for tissue repair and/or augmentation, or as a scaffold to support tissue regeneration and/or reconstruction. In some embodiments, the compositions described herein can be used for soft tissue repair or augmentation.

Disclosed is a method for filling a root canal in a tooth. The method includes positioning a fiber in the root canal of the tooth, filling at least a portion of the root canal with an unset hydrogel composition, such that the unset hydrogel composition contacts at least a portion of the fiber, setting the hydrogel composition, thereby forming a set hydrogel, and removing the fiber from the set hydrogel, thereby leaving a channel in the set hydrogel. Methods and kits for repairing teeth are also described.

The invention relates to a process for obtaining a skin substitute, comprising the following steps: a) mixing fibroblasts, endothelial cells and hydrogel of exclusively biological origin; b) incubating the mixture obtained in step a) for a sufficient time and under suitable conditions to obtain a pre-vascularized dermis; c) adding keratinocytes to the pre-vascularized dermis of step b) to obtain a skin substitute; wherein said fibroblasts, endothelial cells and keratinocytes were obtained from pluripotent stem cells.

Disclosed herein are compositions and methods to decellularize an isolated organ or portion thereof. Also disclosed herein are compositions and methods for treatment of disease utilizing a decellularized or recellularized organ. Also disclosed herein are methods of improving decellularization and/or recellularization of an isolated organ or portion thereof.

A delivery device or patch is disclosed that includes a detachable hybrid microneedle depot (d-HMND) for cell delivery. The system includes, in one embodiment, an array of microneedles formed from an outer PLGA shell and an internal gelatin methacryloyl (GelMA)-mesenchymal stem cells (MSC) mixture (GMM). The array of microneedles project from a base substrate layer that may be flexible. The therapeutic device may be applied to a tissue site of interest and the base substrate layer is removed leaving the hybrid microneedles in the tissue at the site of application to deliver MSCs. Other stem/therapeutic cells may also be delivered with the hybrid microneedles.